Severe cutaneous eruptions on telaprevir  by Chen, Steven T. & Wu, Peggy A.
References
[1] Parker HM, Johnson NA, Burdon KA, Cohn JS, OConnor HT, George J. Omega-3
supplementation and non-alcoholic fatty liver disease: a systematic review
and meta-analysis. J Hepatol 2012;56:944–951.
[2] Kris-Etherton PM, Harris WS, Appel LJNutrition Committee of the American
Heart Association. Fish consumption, ﬁsh oil, omega-3 fatty acids, and
cardiovascular disease [Erratum appears in Circulation 2003;107:512].
Circulation 2002;106:2747–2757.
Helen M. Parker
Discipline of Exercise and Sport Science,
The University of Sydney, Australia
Nathan A. Johnson
Discipline of Exercise and Sport Science,
The University of Sydney, Australia
Institute of Obesity, Nutrition, Exercise and Eating Disorders,
The University of Sydney, Australia
⇑NAFLD will depend on an assessment by the clinician of whether
in fact he/she has cardiac or other co-morbidities.
We found no reports of adverse events for omega-3 supple-
mentation in the relatively limited pool (nine) of studies, which
met the criteria for inclusion in our review. However, we whole-
heartedly agree that these shouldnot be used to reﬂect the consen-
sus of all intervention trials involving omega-3 supplementation.
As Drs. Li and Chen have correctly highlighted, side-effects of
omega-3 supplementation have been reported in previous studies,
which did not have liver fat and serum aminotransferases as inclu-
sion criteria [2].
Our study provides an important ﬁrst step in establishing an
hepatic beneﬁt of omega-3 therapy in adults, but caution should
be taken when interpreting the clinical implications of the meta-
analysis. Our ﬁndings should serve as a stimulus for future
research examining issues such as dose-responsiveness, safety
and patient tolerance with omega-3 therapy.
Letters to the EditorConﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Jacob George
Storr Liver Unit, Department of Medicine, Westmead Millennium
Institute and Westmead Hospital,
The University of Sydney, Westmead, NSW 2145, Australia⇑Corresponding author. Tel.: +61 02 9845 7705; fax: +61 9635 7582
E-mail addresses: jacob.george@sydney.edu.au,
jacob_george@wmi.usyd.edu.au
Severe cutaneous eruptions on telaprevirTo the Editor:
Since its approval by the Food and Drug Administration in May
2011, telaprevir, a novel serine protease inhibitor, in combination
with peginterferon and ribavirin has been increasingly used as an
effective treatment for hepatitis C virus (HCV) [1]. In phase II and III
clinical trials involving over 3800 patients, a cutaneous eruption,
usually eczematous, occurred in 56% of patients compared to 34%
taking peginterferon and ribavirin alone [2]. Furthermore, 3.7% of
telaprevir-treated patients developed severe cutaneous adverse
events. These events included 11 patients considered to have drug
reactionwith eosinophilia and systemic symptoms (DRESS), but of
these, only one was deﬁnite, two were probable, and the remain-
ders were possible, according to diagnostic criteria proposed by
Kardaun et al. [2,3]. Herein, we report three patients out of 56
patients at risk (5%) taking telaprevir, peginterferon, and ribavirin
at our institution, who developed probable and deﬁnite DRESS.
Case 1
A 60-year-old man with cirrhosis of the liver in week seven of
treatment with telaprevir, ribavirin, and peginterferon alfa-2A
for chronic HCV was admitted for fever of 39 C, new shoulder
pain, and rash of four-day duration. The patient had previously
failed conventional treatment with peginterferon and ribavirin.
On telaprevir-based therapy, his HCV viral load (VL) was reduced
from >9 million copies IU/ml prior to therapy, to undetectable
after four weeks. Partially blanchable, bright, erythematous pap-
ules coalescing into larger plaques covered most of the patient’s470 Journal of Hepatology 20extremities, chest, abdomen, and back (Fig. 1). The morphology
of the rash was consistent with DRESS and involved >50% of his
body surface area (BSA). The skin was pruritic but without ten-
derness, blisters, mucous membrane involvement, facial swelling,
nor lymphadenopathy; however, he had left shoulder pain. On
laboratory data, he was noted to have an absolute eosinophilia
of 805 cells/ll (normal 0–500 cells/ll), thrombocytopenia of
37 K/ll (normal 150–400 K/ll), atypical lymphocytes, and eleva-
tions in alanine and asparate aminotransferases to 45 and 74,
respectively (normal 0–40 IU/L), thus fulﬁlling over ﬁve diagnos-
tic criteria for a deﬁnite case of DRESS [3]. All three antiviral ther-
apies were discontinued. A skin biopsy demonstrated eosinophils
and was consistent with DRESS. He was managed symptomati-
cally with topical class I corticosteroids and systemic antihista-
mines. Unfortunately, 2 months after discontinuation of his
antivirals, his HCV VL has returned to >5 million IU/ml, and he
is being considered for combination therapy with boceprevir,
ribavirin and peginterferon.
Case 2
A 55-year-old female who previously relapsed after peginterfer-
on and ribavirin therapy had a diffuse, pruritic rash, myalgia,
fever, and chills for one month prior to admission. She had been
taking telaprevir, ribavirin, and peginterferon alfa-2A for chronic
HCV with cirrhosis and had an undetectable VL after 8 weeks.
One week prior to admission, she ﬁnished her 12-week course
of telaprevir and remained on ribavirin and peginterferon. Her12 vol. 57 j 467–477
Addendum
Some experts may require more stringent criteria for liver
involvement (elevated alanine aminotransferase twice the upper
limit of normal on at least two occasions) and lymph node
involvement (lymphadenopathy greater than 1 cm for two ana-
tomic sites). By those criteria our series would be considered
two probable and one possible case of DRESS [4].
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Case 1 Case 2 Case 3
Fig. 1. Cutaneous ﬁndings consistent with DRESS. (Case 1) Indurated, bright,
erythematous conﬂuent papules coalescing into plaques on the chest, abdomen,
back, and upper extremities. There were purpuric plaques on his lower
extremities and few erythematous papules on the palms. No blisters or mucosal
lesions were noted. (Case 2) Bright pink, erythematous plaques with ﬁne scale
conﬂuent over 90% of the body surface area. No blisters or mucosal lesions were
noted. (Case 3) Indurated, bright pink-red, conﬂuent papules coalescing into
plaques on the face (not shown), chest, abdomen, back, upper and lower
extremities. No blisters or mucosal lesions were noted.
JOURNAL OF HEPATOLOGYexam revealed conﬂuent, pink, erythematous plaques with ﬁne
scale covering 90% of her BSA and yellow crusts on her lips and
chest (Fig. 1). The rash was consistent with an erythrodermic
drug eruption. Skin and blood cultures revealed Staphylococcus
aureus superinfection and bacteremia. There was no lymphade-
nopathy, blisters, or mucous membrane involvement. On labora-
tory data, she had an absolute eosinophilia of 1435 cells/ll
(normal 0–500 cells/ll), thrombocytopenia of 93 K/ll (normal
150–400 K/ll), and aspartate aminotransferase of 78 (normal
0–40 IU/L), thus fulﬁlling over ﬁve diagnostic criteria for a deﬁ-
nite case of DRESS [3]. A skin biopsy showed eosinophils and
was consistent with a drug reaction. The remaining antiviral
medications were discontinued, and she was managed with anti-
biotics, topical class I corticosteroids and systemic antihista-
mines. Two months after completing her 12-week course of
telaprevir-based HCV therapy, her VL remained undetectable.
Case 3
A 56-year-old female, previous non-responder to peginterferon
and ribavirin was seen at dermatology clinic for diffuse, indu-
rated, erythematous plaques (Fig. 1) and arthralgias of 10-day
duration. She had completed seven weeks of HCV treatment with
telaprevir, ribavirin, and peginterferon alfa-2A and her HCV VL
was undetectable. She was admitted for fever of 38.5 C, syncope,
and worsening rash, involving 80% of her BSA, morphologically
consistent with DRESS. There was no facial swelling, mucous
membrane involvement, or blisters. Left inguinal lymphadenopa-
thy of 1 cm was noted. Laboratory data showed an absolute
eosinophilia of 1045 cells/ll (normal 0–500 cells/ll), thrombocy-
topenia of 83 K/ll (normal 150–400 K/ll), atypical lymphocytes,
and normal liver function tests. She fulﬁlled ﬁve diagnostic crite-
ria for a probable case of DRESS [3]. A skin biopsy was consistent
with a drug hypersensitivity reaction. All antiviral therapies were
discontinued at initial presentation and class I topical corticoste-
roids and antihistamines were initiated. Unfortunately, one
month after discontinuation of therapy, her HCV VL was again
detectable (91,100 IU/ml). A repeat HCV VL was drawn three
months after this episode and it was >2 million IU/ml.
We present three patients who, after at least seven weeks of
telaprevir combined with ribavirin and peginterferon, had severeJournal of Hepatology 20cutaneous adverse reactions that met criteria for probable and
deﬁnite DRESS necessitating discontinuation of therapy (see
Addendum). Typical of DRESS, these patients developed symp-
toms many weeks later in the treatment course than is observed
with other drug reactions. These three patients presented within
a month of each other and represent a higher rate of DRESS
following combined telaprevir therapy than previously reported.
DRESS is a potentially life threatening syndrome with a reported
mortality of up to 10% [5]. It has the potential to affect visceral
organs, most commonly liver, kidney, lung [5], and new reports
have also highlighted a DRESS-related myocarditis [6]. The path-
ophysiologic mechanism of DRESS is not completely understood;
however, current theory ascribes immunologic activation due to
drug metabolite formation as the main mechanism [5]. DRESS
is treated with withdrawal of the offending medication, symp-
tomatic management, and potential systemic immunosuppres-
sion [7]. In order to avoid concerns regarding the suppression
of antiviral response, however, systemic immunosuppression
was avoided. When compared to the study population in previ-
ous reports, our sample size is markedly smaller, and the higher
incidence rate may be an anomaly; however, we feel with
increasing use of telaprevir, further monitoring of severe adverse
event incidence will be critical in determining true risk for poten-
tial patients. While the majority of patients treated with telapre-
vir develop benign drug eruptions [8], these three cases of DRESS
emphasize that with the increasing use of telaprevir, clinicians
need to be aware of potentially life-threatening reactions.12 vol. 57 j 467–477 471
effects of drugs with systemic symptoms: does a DRESS syndrome really
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HCV infection, HOMA index and sustained virological response:
The step we need to take before moving forward
index. The higher the accuracy of the predictive system, the
higher the optimization of HCV treatment and the development
of new antiviral drugs make it imperative.
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Letters to the EditorTo the Editor:
We read with great interest the recent meta-analysis by Deltenre
et al. [1]. Authors included 14 studies involving 2732 HCV-posi-
tive patients and showed that insulin-resistance (IR) has an
evident negative association with the possibility of achieving a
sustained virological response (SVR) to Peg-Interferon and
ribavirin, in particular in patients with genotype 1 infection. As
discussed, some important limitations do not allow an indepen-
dent association of IR with treatment failure to be highlighted.
Other predictive factors, genetic and non-genetic, could be
behind this association such as IL-28 polymorphism, ﬁbrosis,
age, viremia, presence of steatosis and other clinical variables
associated with the metabolic syndrome. Hence, a real cause-
effect relation is still an open question, and a sort of ‘‘dose effect’’
of IR on SVR has never been exhaustively explored. We believe
that investigations aimed at solving these issues are a priority
area of research in order to optimize the management of HCV
patients. In accordance with the results by Walsh et al. [2],
authors argued the overexpression of suppressor of cytokine
signaling (SOCS-3) induced by HCV as one of the mechanisms
evoked to explain the association of the metabolic syndrome with
non-response to antiviral therapy. However, they consider this
observation as never conﬁrmed by other studies. Nevertheless,
we wish to point out that Huang et al. [3] and our personal data
[4] have conﬁrmed the overexpression of SOCS-3 in the liver of
non-responders to antiviral therapy. Moreover, in vitro data by
our group suggested that this is dependent on the genotype, giv-
ing an indirect clue that, if an interference of HCV with insulin
signaling exists, it could be mainly due to genotype 1 infection
[5], but the debate is still open [6]. Deltenre et al. also stated that
the HOMA-IR index measured prior to antiviral therapy could be
useful to implement a potential combined score at basal evalua-
tion to predict treatment response. We totally agree with this
statement but we probably need to take a step before moving for-
ward. The individual value of HOMA-IR index has been largely
discussed [7]. Exploring the possibility of a dose effect of IR on
SVR is probably the ﬁrst step to take as a reliable cut-off to deﬁne
the presence of IR by HOMA does not exist, neither the reproduc-
ibility of a speciﬁc cut-off in patients with or without clinical
features of metabolic syndrome has ever been explored. All these
aspects, presently, do not allow taking a step forward in terms of
further predicting SVR in HCV patients by using the HOMA-IR472 Journal of Hepatology 2012 vol. 57 j 467–477
